key: cord-1002264-l1mb1hir
authors: Aguilar-Shea, Antonio L.; Gutiérrez-Martín-Arroyo, Joaquín; Vacas-Córdoba, Miguel; Gallardo-Mayo, Cristina
title: Reinfección por SARS-CoV-2: la primera en una familia reportada en España
date: 2021-05-07
journal: Med Clin (Barc)
DOI: 10.1016/j.medcli.2021.04.009
sha: 54a53214c90c78ad1df5e6b52086ed120ddf9062
doc_id: 1002264
cord_uid: l1mb1hir

nan

To the editor. We present a healthy family that live in Spain. Parents are health care workers, the father, Family Physician and the mother, Anaesthetist; they have three children, two boys aged 8 and 6 years and 4 years girl. The suspected first contact that the family had with the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was mid-February 2020 when the 8 year-old-boy complained for 2 days of intermittent headache, stomach pain and general malaise with no fever or any other symptom. He was treated with occasional acetaminophen; symptoms resolved with a full recovery. No other family member reported any symptoms at the time.

In mid-March 2020 the husband, a 39 year-old Family Physician (FP) was a confirmed case of Coronavirus disease 2019 (COVID-19) by a positive reverse-transcription polymerase chain reaction (RT-PCR) test from a oropharyngeal sample and a negative nasopharyngeal RT-PCR test 14 days later. At the time he described 2 days of sore throat, followed by fever up to 38.8ºC, general malaise and nasal congestion for 3 days, exertional tachycardia and chest pain for 2 days and loss of smell and taste for about one month. Symptomatic treatment was given with acetaminophen for 5 days and then as needed. He experienced a full recovery and went back to normal life activities.

By mid-April 2020 the family was tested with rapid antibody tests. The wife, 4-year-girl and 6-year-boy were negative, the FP was positive with IgM and IgG lines and the 8year-old boy positive with no IgM line and a strong IgG line. It was suspected that the child's symptoms from February were actually caused by coronavirus, since no other infectious disease was reported, and it coincided with the suspicion that coronavirus was already in circulation in Spain at the time. In August 2020 the blood test was done by FP, Immunoglobulin (Ig)G antibody for SARS-CoV-2 was positive 6.4 (<1.6), no IgM was reported.

J o u r n a l P r e -p r o o f Time passed and both physicians kept working and then, in the beginning of January 2021, with the 3 rd national and world COVID19 wave, the healthy 39-year-old Anaesthetist, presented with a mild odynophagia that was followed the next day by general myalgias, feverish sensation with a temperature of 36.4ºC, slight general discomfort and nasal congestion. Antigen rapid test was done within a positive result with in the first 2 minutes with a strong positive line. Isolation from the rest of the family members was hard to follow and apparently the husband and the 8-year-old boy were immune. Over the next 2 days, she suffered a slight headache, myalgias and general malaise. She then associated loss of taste and smell and for 2 days she complained of intense triceps and external thigh area muscle pain that resolved in 2 days. At day 7 antigen test was repeated, being still positive, taking longer to give the result and with a less intense line. No fever, cough, dyspnoea or chest pain were ever reported. Symptoms progressively resolved with persistence of loss of smell and taste. At day 11 the antigen test was repeated and found negative. She received symptomatic treatment with acetaminophen which she took occasionally.

Two days later after the wife´s initial symptoms, the husband described an uncomfortable night sleep and waking up with a sore throat, that morning the rapid antigen test was negative. The next day a blood test to review SARS-CoV-2 immunity was done revealing positive IgG antibodies 29.30 (<9). The sore throat persisted, with slight general malaise, nasal congestion and some nasal discharge. The following day, day 3, due to symptoms persistence, a second rapid antigen test was done with a light positive result, not with in the first 5 minutes. Tiredness, malaise, nasal congestion and discharge persisted, with no fever or cough over the next days. Symptoms were described as the usual for a cold.

Another 2 days passed, rapid antigen test was repeated with a fast strong positive result, that day nasopharyngeal RT-PCR test was done and was found to be POSITIVE, cycle On the 7 th day of the mother´s symptoms and 4 th day of the initial symptoms of the father, rapid antigen test was done on the 3 asymptomatic children being all 3 negative. A week later it was repeated, being also negative. The 3 children did not show any symptoms, except for the 6 year-old-boy that complained of nasal congestion for 2 days that did not require any treatment and who did not suffer any loss of energy. 2 days later the previously described antigen test was done on all 3 children.

Two weeks later the rapid total antibody tests were done on all 5 family members: mother and father were positive, the 8 year-old boy and the 4 year-old girl were negative and the 6 year-old-boy was POSITIVE.

All family members experienced a full recovery and progressively reassumed their daily routines. Figure 1 . Since the beginning of the infections, there has always been a concern about the possibility of reinfections. Coronaviruses are considered stable viruses that limit mutation, errors in RNA sequence, due to a "correcting" enzyme. Data suggest that overall, the short-term risk of reinfection appears low, a study of UK health-care workers showed that reinfection with SARS-CoV-2 is uncommon up to 6 months after the primary infection.

Page 6 of 9 J o u r n a l P r e -p r o o f

To analyse the available data on reinfection a search in Medline(Pubmed) was done on March 1 st 2021 using key words "COVID19", "SARS-CoV-2"and "reinfection".

Reinfections are being described related with different viral strains 2,3 , so even though the virus is stable it still has the capacity to mutate and avoid the immune system. Sequencing that demonstrates a different strain at the time of presumptive reinfection is necessary to make the distinction. Different viral strains have been described in Europe, South Africa, Ongoing cases of COVID19 and the vaccination programs all over the world will hopefully lead to quicker herd immunity and will stop putting in jeopardy all the health care systems all over the world.

Although the virus is quite stable, it has had access to so many people and has replicated in a virgin human community so the capability of mutations is at its peak.

Reinfection with SARS-CoV-2 is a possibility, this case explains that infections do not provide long-term immunity and that the virus has the ability to mutate and avoid the immune system. We consider that by adding the number of those recovered from the natural infection to those vaccinated, we will have increased the number of humans that have been in contact the virus. The re-exposure to different virus strains will happen, since the mutations capability of the virus has been proven. The immunity generated from the vaccination or natural infection should be able to recognise different virus strains, providing sufficient protection for milder forms of COVID19, such as the case reported.

Is the virus here to stay? Will it become another common cold virus like HCoV-NL63, HCoV-229E, HCoV-OC43 and HKU1? Answers to these questions will be known in the coming months.

None.

Why the immune system fails to mount an adaptive immune response to a COVID-19 infection

Evidence of SARS-CoV-2 reinfection with a different genotype

Genomic evidence for reinfection with SARS-CoV-2: a case study

SARS-CoV-2 Variants

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases